COVID -19 Vaccines Amidst Emerging Delta Variant: Review

Abstract

In this unprecedented Covid-19 pandemic when the secondary wave of the pandemic is just about to get over. The most promising solution remains to be an efficient vaccine. Many vaccine candidates are using different platforms of vaccine development using inactivated virus, viral vector, protein subunit, nucleic acid vaccines and their subsequent trials are being carried out. Vaccines with more than 90% efficacy are licensed and beginning roll-out in some countries but still with inconclusive results. Furthermore, with the constant mutation seen in the form of delta or delta plus variant it has become worrisome concern for scientists to develop a vaccine against this virus.